These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28398306)

  • 1. Real world points to SGLT-2 blockers advantage.
    Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398306
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
    Goldberg N; Fralick M
    CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
    [No Abstract]   [Full Text] [Related]  

  • 3. [Introduction].
    García SD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
    [No Abstract]   [Full Text] [Related]  

  • 4. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
    Miller K; Miller EM
    J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
    Ghosh A; Gupta R; Misra A
    J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
    [No Abstract]   [Full Text] [Related]  

  • 6. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glycosuria with SGLT-2 inhibitors--a new treatment approach for type 2 diabetes mellitus].
    Rosak C; Forst T
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():95-101. PubMed ID: 23326927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 9. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 10. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 11. [Positive experience with SGLT-2 inhibitor in general practice].
    Fath R
    MMW Fortschr Med; 2015 Jul; 157(13):83. PubMed ID: 26206058
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
    Santos LL; Lima FJC; Sousa-Rodrigues CF; Barbosa FT
    Rev Assoc Med Bras (1992); 2017 Jul; 63(7):636-641. PubMed ID: 28977090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
    Bloomgarden Z
    J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Mauricio D
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
    Dalama B; Biagetti B; Mesa J
    Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
    [No Abstract]   [Full Text] [Related]  

  • 17. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
    Riser Taylor S; Harris KB
    Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.